Rafael Oania1, Linda K McEvoy2. 1. John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA. 2. Department of Radiology, University of California, San Diego, 9500 Gilman Dr MC 0841, La Jolla, CA 92037, USA.
Abstract
BACKGROUND: animal studies suggest a neuroprotective role for leptin, but human studies have shown mixed results. We examined whether plasma leptin levels in individuals with mild cognitive impairment (MCI) were related to cognitive function at baseline and whether higher leptin levels were associated with reduced risk of dementia. METHODS: we categorised 352 MCI participants into sex-specific tertiles based on log-transformed fasting plasma leptin levels. In sex-stratified analyses, we investigated whether cognitive ability differed by leptin tertile. We also examined whether the risk of dementia over a 3-year follow-up period differed by leptin level. Analyses controlled for numerous potential confounding variables, including body mass index, hypertension and levels of blood insulin and C-reactive protein. RESULTS: baseline cognitive ability did not differ as a function of leptin level, nor were higher leptin levels associated with reduced hazard of developing dementia. Controlling for related co-variates did not reveal any significant associations between leptin and dementia risk. CONCLUSION: in this cohort of older adults with MCI, plasma leptin level was not associated with cognitive function at baseline, nor did it predict risk of dementia. Other biological measures, such as volumetric MRI and cerebrospinal fluid protein levels, have demonstrated robust dementia prediction in this cohort. Thus, the current negative findings suggest that plasma leptin, on its own, is unlikely to become a useful clinical biomarker for Alzheimer's disease. Efforts to develop other blood-based biomarkers are needed.
BACKGROUND: animal studies suggest a neuroprotective role for leptin, but human studies have shown mixed results. We examined whether plasma leptin levels in individuals with mild cognitive impairment (MCI) were related to cognitive function at baseline and whether higher leptin levels were associated with reduced risk of dementia. METHODS: we categorised 352 MCI participants into sex-specific tertiles based on log-transformed fasting plasma leptin levels. In sex-stratified analyses, we investigated whether cognitive ability differed by leptin tertile. We also examined whether the risk of dementia over a 3-year follow-up period differed by leptin level. Analyses controlled for numerous potential confounding variables, including body mass index, hypertension and levels of blood insulin and C-reactive protein. RESULTS: baseline cognitive ability did not differ as a function of leptin level, nor were higher leptin levels associated with reduced hazard of developing dementia. Controlling for related co-variates did not reveal any significant associations between leptin and dementia risk. CONCLUSION: in this cohort of older adults with MCI, plasma leptin level was not associated with cognitive function at baseline, nor did it predict risk of dementia. Other biological measures, such as volumetric MRI and cerebrospinal fluid protein levels, have demonstrated robust dementia prediction in this cohort. Thus, the current negative findings suggest that plasma leptin, on its own, is unlikely to become a useful clinical biomarker for Alzheimer's disease. Efforts to develop other blood-based biomarkers are needed.
Authors: Gail A Laughlin; Linda K McEvoy; Denise von Mühlen; Lori B Daniels; Donna Kritz-Silverstein; Jaclyn Bergstrom; Kevin Cummins; Claudia Der-Martirosian; Simerjot K Jassal; Elizabeth Barrett-Connor Journal: Psychosom Med Date: 2011-09-23 Impact factor: 4.312
Authors: Linda K McEvoy; Gail A Laughlin; Elizabeth Barrett-Connor; Jaclyn Bergstrom; Donna Kritz-Silverstein; Claudia Der-Martirosian; Denise von Mühlen Journal: Ann Epidemiol Date: 2012-01-29 Impact factor: 3.797
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Michal Figurski; Els Coart; Kaj Blennow; Holly Soares; Adam J Simon; Piotr Lewczuk; Robert A Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2011-02-11 Impact factor: 17.088
Authors: William A Banks; Alan B Coon; Sandra M Robinson; Asif Moinuddin; Jessica M Shultz; Ryota Nakaoke; John E Morley Journal: Diabetes Date: 2004-05 Impact factor: 9.461
Authors: M Vaňková; G Vacínová; J Včelák; D Vejražková; P Lukášová; R Rusina; I Holmerová; E Jarolímová; H Vaňková; B Bendlová Journal: Physiol Res Date: 2020-09-30 Impact factor: 1.881
Authors: A Veronica Witte; Theresa Köbe; Anders Graunke; Jan Philipp Schuchardt; Andreas Hahn; Valentina A Tesky; Johannes Pantel; Agnes Flöel Journal: Hum Brain Mapp Date: 2016-08-11 Impact factor: 5.038
Authors: Malgorzata Gorska-Ciebiada; Malgorzata Saryusz-Wolska; Anna Borkowska; Maciej Ciebiada; Jerzy Loba Journal: Metab Brain Dis Date: 2015-10-02 Impact factor: 3.584
Authors: Han Yin; Sai Tian; Rong Huang; Rongrong Cai; Dan Guo; Hongyan Lin; Jiaqi Wang; Shaohua Wang Journal: Front Aging Neurosci Date: 2018-05-15 Impact factor: 5.750